Brought to you by 
Biogen, Skyhawk team up in the CNS space
18 Jul 2019
Executive Summary
Biogen Inc. and Skyhawk Therapeutics Inc. are teaming up to develop small-molecule therapeutics for neurological diseases including multiple sclerosis and spinal muscular atrophy using the SkySTAR platform.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen, Skyhawk team up in the CNS space
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice